Investigational drug · Phase 3
TY-9591
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for NSCLC, EGFR Activating Mutation, Brain Metastases.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 25, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
8
Any phase or sponsor naming "TY-9591"
First trial start
2022
Jun 8, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TY-9591", any sponsor or status.
Conditions studied
As listed on its trial records.
- NSCLC
- EGFR Activating Mutation
- Brain Metastases
Approved drugs for the same conditions: Non-small cell lung cancer
Largest trials
Live from ClinicalTrials.gov: studies naming "TY-9591" as an intervention, largest first.
- Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)Pivotal-lookingRecruiting
TYK Medicines, IncIndustry
NCT05382728 · 680 participants (planned) · Start Jun 8, 2022 · Primary completion May 2025
Drug: TY-9591; placebo Osimertinib and 2 more · For: NSCLC; EGFR Activating Mutation
Sites: Changsha, China; Shanghai, China
- TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain MetastasesPivotal-lookingRecruiting
TYK Medicines, IncIndustry
NCT05948813 · 420 participants (planned) · Start Aug 17, 2023 · Primary completion Dec 15, 2025
Drug: TY-9591; Osimertinib · For: NSCLC; EGFR Activating Mutation; Brain Metastases
Sites: Beijing, China
TYK Medicines, IncIndustry
NCT04204473 · 105 participants · Start May 7, 2020 · Primary completion Mar 3, 2023
Drug: TY-9591(10mg,40mg) qd. po · For: NSCLC
Sites: Shanghai, China
- A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLCNot yet recruiting
TYK Medicines, IncIndustry
NCT06672068 · 60 participants (planned) · Start Feb 20, 2025 · Primary completion Dec 1, 2027
Drug: TY-9591 80mg QD+pemetrexed+Cisplatin/Carboplatin; TY-9591 160mg QD+pemetrexed+Cisplatin/Carboplatin · For: NSCLC
TYK Medicines, IncIndustry
NCT06255951 · 48 participants · Start Mar 12, 2024 · Primary completion May 23, 2024
Drug: Itraconazole; Rifampicin · For: NSCLC
Sites: Guangdong, China
TYK Medicines, IncIndustry
NCT05146219 · 29 participants · Start Apr 2, 2022 · Primary completion Mar 21, 2024
Drug: TY-9591 Tablets · For: NSCLC; EGFR Activating Mutation; Brain Metastases and 1 more
Sites: Beijing, China
- A Study to Assess the Effect of Food on the Pharmacokinetics of TY-9591 in Healthy VolunteersCompleted
TYK Medicines, IncIndustry
NCT04798638 · 16 participants · Start Apr 30, 2021 · Primary completion Sep 9, 2021
Drug: TY-9591 Tablets under Fasted Condition - Arm1; Osimertinib Mesylate Tablets under Fasted Condition - Arm1 and 4 more · For: Healthy Volunteers
Sites: Changsha, China
TYK Medicines, IncIndustry
NCT05871905 · 6 participants · Start Jun 19, 2023 · Primary completion Nov 6, 2023
Drug: TY-9591 · For: Healthy Volunteers
Sites: Suzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- Old Wine in New Bottles? Deuterium Switch (Replacing Hydrogen With Deuterium) Comes to Thoracic Oncology as Deuterated Lorlatinib (Deulorlatinib, TGRX-326) and Deuterated Osimertinib (Asandeutertinib, TY-9591) in ALK+ NSCLC and EGFR+ NSCLC, Respectively.
Park CJ, Li MS, Ou SI · J Thorac Oncol 2025
- Safety, Pharmacokinetics, and Efficacy of Asandeutertinib in Advanced EGFR-mutated NSCLC: A Phase 1 Dose-Escalation and Dose-Expansion Study.
Han B, Liu J, Wu L, et al. · J Thorac Oncol 2025
Also in development for NSCLC
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- JAB-21822Glecirasib Citrate, KRAS G12C inhibitorPhase 310 trials
Allist Pharmaceuticals, Inc. · Non-small Cell Lung Cancer, KRAS P.G12C, Solid Tumor
- FurmonertinibPhase 38 trials
Allist Pharmaceuticals, Inc. · Non-Small Cell Lung Cancer, NSCLC, NSCLC Patients With Brain Metastasis
- PetosemtamabMCLA-158, GEN1158Phase 35 trials
Genmab · Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Advanced/Metastatic Solid Tumors
- FirmonertinibAST2818Phase 34 trials
Allist Pharmaceuticals, Inc. · Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer
- zoldonrasibPhase 34 trials
Revolution Medicines, Inc. · Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC
- EIK1001Phase 33 trials
Eikon Therapeutics · Advanced Melanoma, NSCLC, Non Small Cell Lung Cancer (Squamous or Non Squamous)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.